首页 > 最新文献

Fundamental & Clinical Pharmacology最新文献

英文 中文
Differential Effects of Prenatal Poly I:C Exposure and Antipsychotics on NMDA/GABA Receptors and GSK3β-Mediated Signaling in the Dorsal Raphe Nucleus of Female Rats 产前Poly I:C暴露和抗精神病药物对雌性大鼠中缝背核NMDA/GABA受体和gsk3 β介导的信号传导的差异影响
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-25 DOI: 10.1111/fcp.70033
Shiyan Chen, Jiamei Lian, Yueqing Su, Chao Deng

Background

The dorsal raphe nucleus (DRN) is the origin of the 5-HT neurotransmission pathways. The 5-HT, dopamine D2, GABA, and NMDA receptors, as well as the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) and G protein-independent protein kinase B (PKB/Akt)-glycogen synthase kinase 3β (GSK3β) signaling, are involved in the pathophysiology of schizophrenia and are modulated by antipsychotics. However, their pathological changes and antipsychotic modulations in the DRN are not well understood in schizophrenia.

Objectives

This study explored effects of antipsychotics on NMDA and GABAA receptors, as well as PKA, AKT-GSK3β, cAMP-responsive element-binding protein 1 (CREB1), and disheveled (Dvl)-β-catenin signaling in the DRN using a maternal immune activation rat model.

Methods

Prenatal polyriboinosinic-polyribocytidylic acid (Poly I:C) exposure was delivered at gestational Day 15. Female rats were treated with risperidone, olanzapine, or vehicle from postnatal day 70 for 35 days.

Results

Prenatal Poly I:C exposure increased mRNA expression of NMDA receptor Grin2a/2b subunits, the GABAA receptor β3 subunit, glutamic acid decarboxylase 1 (GAD1), AKT1/3, and GSK3β in the DRN. Antipsychotics significantly increased the mRNA expression of PKA, CREB1, β-catenin, GSK3β, and Grin2d subunits in the DRN of Poly I:C rats. Prenatal Poly I:C exposure led to decreased expression of GAD2, which was partially reversed antipsychotics.

Conclusion

This study suggests that prenatal Poly I:C exposure and antipsychotics differentially modulate NMDA and GABAA receptors, as well as AKT-GSK3β, PKA-CREB1, and Dvl-β-catenin signaling in the DRN of rats. Poly I:C mainly influenced the AKT-GSK3β signaling, while antipsychotics modulated the AKT-GSK3β, PKA-CREB1, and Dvl-GSK3β-β-catenin signaling pathways in the DRN.

中缝背核(DRN)是5-HT神经传递通路的起源。5-HT、多巴胺D2、GABA和NMDA受体以及环腺苷单磷酸(cAMP)-蛋白激酶A (PKA)和G蛋白独立蛋白激酶B (PKB/Akt)-糖原合成酶激酶3β (GSK3β)信号通路参与了精神分裂症的病理生理,并受到抗精神病药物的调节。然而,它们在精神分裂症中的病理改变和DRN的抗精神病调节作用尚不清楚。目的利用母体免疫激活大鼠模型,探讨抗精神病药物对DRN中NMDA和GABAA受体以及PKA、AKT-GSK3β、cAMP-responsive element-binding protein 1 (CREB1)和disheveled (Dvl)-β-catenin信号的影响。方法在妊娠第15天给予产前多核糖素-多核糖素(Poly I:C)暴露。雌性大鼠从出生后第70天开始分别给予利培酮、奥氮平或对照物治疗,持续35天。结果产前Poly I:C暴露增加了DRN中NMDA受体Grin2a/2b亚基、GABAA受体β3亚基、谷氨酸脱羧酶1 (GAD1)、AKT1/3和GSK3β mRNA的表达。抗精神病药物显著增加Poly I:C大鼠DRN中PKA、CREB1、β-catenin、GSK3β和Grin2d亚基的mRNA表达。产前Poly I:C暴露导致GAD2表达降低,部分逆转抗精神病药物的作用。结论产前Poly I:C暴露和抗精神病药物对大鼠DRN中NMDA和GABAA受体以及AKT-GSK3β、PKA-CREB1和Dvl-β-catenin信号通路的影响存在差异。Poly I:C主要影响AKT-GSK3β信号通路,而抗精神病药物则调节DRN中AKT-GSK3β、PKA-CREB1和Dvl-GSK3β-β-catenin信号通路。
{"title":"Differential Effects of Prenatal Poly I:C Exposure and Antipsychotics on NMDA/GABA Receptors and GSK3β-Mediated Signaling in the Dorsal Raphe Nucleus of Female Rats","authors":"Shiyan Chen,&nbsp;Jiamei Lian,&nbsp;Yueqing Su,&nbsp;Chao Deng","doi":"10.1111/fcp.70033","DOIUrl":"https://doi.org/10.1111/fcp.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The dorsal raphe nucleus (DRN) is the origin of the 5-HT neurotransmission pathways. The 5-HT, dopamine D2, GABA, and NMDA receptors, as well as the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) and G protein-independent protein kinase B (PKB/Akt)-glycogen synthase kinase 3β (GSK3β) signaling, are involved in the pathophysiology of schizophrenia and are modulated by antipsychotics. However, their pathological changes and antipsychotic modulations in the DRN are not well understood in schizophrenia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study explored effects of antipsychotics on NMDA and GABA<sub>A</sub> receptors, as well as PKA, AKT-GSK3β, cAMP-responsive element-binding protein 1 (CREB1), and disheveled (Dvl)-β-catenin signaling in the DRN using a maternal immune activation rat model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Prenatal polyriboinosinic-polyribocytidylic acid (Poly I:C) exposure was delivered at gestational Day 15. Female rats were treated with risperidone, olanzapine, or vehicle from postnatal day 70 for 35 days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Prenatal Poly I:C exposure increased mRNA expression of NMDA receptor <i>Grin2a/2b</i> subunits, the GABA<sub>A</sub> receptor <i>β3</i> subunit, glutamic acid decarboxylase 1 (<i>GAD1</i>), <i>AKT1/3</i>, and <i>GSK3β</i> in the DRN. Antipsychotics significantly increased the mRNA expression of <i>PKA</i>, <i>CREB1</i>, <i>β-catenin</i>, <i>GSK3β</i>, and <i>Grin2d</i> subunits in the DRN of Poly I:C rats. Prenatal Poly I:C exposure led to decreased expression of <i>GAD2</i>, which was partially reversed antipsychotics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study suggests that prenatal Poly I:C exposure and antipsychotics differentially modulate NMDA and GABA<sub>A</sub> receptors, as well as AKT-GSK3β, PKA-CREB1, and Dvl-β-catenin signaling in the DRN of rats. Poly I:C mainly influenced the AKT-GSK3β signaling, while antipsychotics modulated the AKT-GSK3β, PKA-CREB1, and Dvl-GSK3β-β-catenin signaling pathways in the DRN.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/fcp.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Master 2 award 二级大师奖
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70019
{"title":"Master 2 award","authors":"","doi":"10.1111/fcp.70019","DOIUrl":"https://doi.org/10.1111/fcp.70019","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discussed poster abstracts—PM2 讨论海报摘要- pm2
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70022
{"title":"Discussed poster abstracts—PM2","authors":"","doi":"10.1111/fcp.70022","DOIUrl":"https://doi.org/10.1111/fcp.70022","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug news and therapeutic news 药物新闻和治疗新闻
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70017
{"title":"Drug news and therapeutic news","authors":"","doi":"10.1111/fcp.70017","DOIUrl":"https://doi.org/10.1111/fcp.70017","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral communication abstracts 口头交流摘要
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70018
{"title":"Oral communication abstracts","authors":"","doi":"10.1111/fcp.70018","DOIUrl":"https://doi.org/10.1111/fcp.70018","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thesis awards 论文奖
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70020
{"title":"Thesis awards","authors":"","doi":"10.1111/fcp.70020","DOIUrl":"https://doi.org/10.1111/fcp.70020","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discussed poster abstracts—PM1 讨论海报摘要- pm1
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70021
{"title":"Discussed poster abstracts—PM1","authors":"","doi":"10.1111/fcp.70021","DOIUrl":"https://doi.org/10.1111/fcp.70021","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Poster abstracts 海报摘要
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70023
{"title":"Poster abstracts","authors":"","doi":"10.1111/fcp.70023","DOIUrl":"https://doi.org/10.1111/fcp.70023","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Theme and main topic index 主题和主题索引
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-23 DOI: 10.1111/fcp.70024
{"title":"Theme and main topic index","authors":"","doi":"10.1111/fcp.70024","DOIUrl":"https://doi.org/10.1111/fcp.70024","url":null,"abstract":"","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 S1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Factors and Multiple Interaction Effects for Hyperammonemia in Patients Receiving Valproic Acid 丙戊酸治疗患者高氨血症的危险因素及多重相互作用
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-06-22 DOI: 10.1111/fcp.70030
Chien-Chou Su, Tsai-Kuei Huang, Ching-Sen Shih, Yi-Chia Su

Background

Valproic acid (VPA) use is associated with an increased risk of hyperammonemia (HA); however, the specific interactions between HA risk factors in VPA-treated patients remain unclear.

Objectives

This study aimed to identify and assess the effects of multiple interactions between different risk factors affecting HA to improve clinical risk stratification in patients undergoing VPA therapy.

Methods

We conducted a retrospective cohort study by reviewing the medical records of patients treated with VPA at a single center from January 2019 to December 2021. The SHapley Additive exPlanations (SHAP) method was used to interpret model predictions, revealing the relative importance and interactions of factors affecting HA risk. SHAP interaction scores were used to assess the effects of multiple interactions between features, providing a comprehensive analysis of how risk factors interact.

Results

This study identified the Top 15 predictors of HA, ranked by importance: patient age, VPA blood concentration, VPA dose, epilepsy, VPA treatment duration, levetiracetam use, hypertension, mental disorders, and number of medications. Notable multiple interaction effects were observed, particularly between age and factors including VPA concentration, epilepsy, and treatment duration. Younger patients and those with elevated VPA concentrations were at increased risk of developing HA, especially when epilepsy or polypharmacy were present.

Conclusions

This study highlights several critical factors potentially influencing HA development in VPA-treated patients, particularly younger patients, those with epilepsy, or those undergoing polypharmacy. However, as a single-center retrospective study, these findings necessitate further validation through additional research.

背景丙戊酸(VPA)的使用与高氨血症(HA)的风险增加有关;然而,在vpa治疗的患者中,HA危险因素之间的具体相互作用尚不清楚。本研究旨在识别和评估影响HA的不同危险因素之间多重相互作用的影响,以改善VPA治疗患者的临床风险分层。方法通过回顾2019年1月至2021年12月在单一中心接受VPA治疗的患者的病历,进行回顾性队列研究。使用SHapley加性解释(SHAP)方法解释模型预测,揭示影响HA风险的因素的相对重要性和相互作用。SHAP相互作用评分用于评估特征之间多重相互作用的影响,提供了对危险因素如何相互作用的全面分析。结果本研究确定了HA的前15个预测因素,按重要性排序:患者年龄、VPA血药浓度、VPA剂量、癫痫、VPA治疗时间、左乙西坦使用、高血压、精神障碍和药物数量。观察到明显的多重相互作用效应,特别是年龄与VPA浓度、癫痫和治疗时间等因素之间的相互作用。年轻患者和VPA浓度升高的患者发生HA的风险增加,特别是当癫痫或多药并存时。本研究强调了几个可能影响vpa治疗患者HA发展的关键因素,特别是年轻患者、癫痫患者或接受多种药物治疗的患者。然而,作为一项单中心回顾性研究,这些发现需要通过额外的研究进一步验证。
{"title":"Risk Factors and Multiple Interaction Effects for Hyperammonemia in Patients Receiving Valproic Acid","authors":"Chien-Chou Su,&nbsp;Tsai-Kuei Huang,&nbsp;Ching-Sen Shih,&nbsp;Yi-Chia Su","doi":"10.1111/fcp.70030","DOIUrl":"https://doi.org/10.1111/fcp.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Valproic acid (VPA) use is associated with an increased risk of hyperammonemia (HA); however, the specific interactions between HA risk factors in VPA-treated patients remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to identify and assess the effects of multiple interactions between different risk factors affecting HA to improve clinical risk stratification in patients undergoing VPA therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study by reviewing the medical records of patients treated with VPA at a single center from January 2019 to December 2021. The SHapley Additive exPlanations (SHAP) method was used to interpret model predictions, revealing the relative importance and interactions of factors affecting HA risk. SHAP interaction scores were used to assess the effects of multiple interactions between features, providing a comprehensive analysis of how risk factors interact.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study identified the Top 15 predictors of HA, ranked by importance: patient age, VPA blood concentration, VPA dose, epilepsy, VPA treatment duration, levetiracetam use, hypertension, mental disorders, and number of medications. Notable multiple interaction effects were observed, particularly between age and factors including VPA concentration, epilepsy, and treatment duration. Younger patients and those with elevated VPA concentrations were at increased risk of developing HA, especially when epilepsy or polypharmacy were present.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study highlights several critical factors potentially influencing HA development in VPA-treated patients, particularly younger patients, those with epilepsy, or those undergoing polypharmacy. However, as a single-center retrospective study, these findings necessitate further validation through additional research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":"39 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Fundamental & Clinical Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1